source · text/markdown
source_05b534e8d14b4ec7
sha256 1eaf4eda70ea507c7df1d94febabac8fa0ce24ef1eb33a54d9da9741415c26a8
by researka:v2 · 2026-05-28 18:30:42.488887+04:00
This synthesis tests the thesis that evidence for CGM glucose variability is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Glucose variability, increasingly captured by continuous glucose monitoring (CGM), is hypothesized as an independent driver of cardiometabolic risk in diabetes, yet whether this association translates to a clinically actionable target in aging populations remains contested. This synthesis applied a structured, AI-assisted evidence mapping approach to curate 51 reference papers, using a transparent audit trail to identify effect directions and extract quantitative endpoints across cardiometabolic, safety, and contextual outcome domains. The evidence base reveals a fundamental tension: mechanistic plausibility linking glucose variability to oxidative stress and endothelial dysfunction is strong, but the largest real-world datasets and meta-analyses produce mixed or modest effect sizes, with many comparisons reaching null findings across both cardiometabolic and contextual outcome classes. Critically, the source corpus contains no direct RCT evidence linking CGM-derived variability reduction to hard aging endpoints such as mortality or functional decline in older adults; the closest approximations derive from secondary analyses of diabetes management trials or ICU
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "758e6e9b-d298-48a7-96bc-c4fda8dc9366",
"title": "Research Synthesis: Cgm Glucose Variability \u2014 full paper"
}